Growth Metrics

Acadia Pharmaceuticals (ACAD) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $71.8 million.

  • Acadia Pharmaceuticals' Profit After Tax rose 11907.22% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 10323.88%. This contributed to the annual value of $226.5 million for FY2024, which is 46949.87% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Profit After Tax stood at $71.8 million for Q3 2025, which was up 11907.22% from $26.7 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Profit After Tax high stood at $143.7 million for Q4 2024, and its period low was -$113.1 million during Q1 2022.
  • Over the past 5 years, Acadia Pharmaceuticals' median Profit After Tax value was -$14.5 million (recorded in 2021), while the average stood at -$5.3 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Profit After Tax plummeted by 13976.75% in 2023, and later soared by 289721.72% in 2024.
  • Acadia Pharmaceuticals' Profit After Tax (Quarter) stood at -$43.1 million in 2021, then grew by 3.18% to -$41.7 million in 2022, then soared by 209.76% to $45.8 million in 2023, then soared by 213.87% to $143.7 million in 2024, then crashed by 50.06% to $71.8 million in 2025.
  • Its Profit After Tax stands at $71.8 million for Q3 2025, versus $26.7 million for Q2 2025 and $19.0 million for Q1 2025.